PYFA Operates Australia’s Largest New Pharmaceutical Plant, Probiotec Officially Obtains Australian TGA License

Jakarta, September 18, 2025 – PT Pyridam Farma Tbk (PYFA), a public company in the pharmaceutical sector, has officially announced that its Australian subsidiary, Probiotec, has commenced operations at its new factory located in Kemps Creek, New South Wales. Probiotec Multipack Kemps Creek becomes the largest and most comprehensive facility for primary and secondary packaging in Australia, spanning 36,000 sqm. This facility specializes in co-packing services for products with GMP/TGA, APVMA, and FMCG standards.

The strategy of consolidating four factories into one larger-scale facility aims for significant overhead cost efficiency, thereby strengthening the company’s growth strategy and business projections in the Australian market. This consolidation is also projected to double production capacity and provide cost efficiencies of AUD 3-5 million per year. It is also noted that facilities with similar scale and specialization are rare in Australia. The pharmaceutical manufacturing and packaging industry in Australia tends to be fragmented, with many companies focusing on specific services or market segments. This consolidation establishes Probiotec as the market leader in pharmaceutical co-packaging in Australia.

In August 2025, Probiotec’s new factory officially obtained a license from the Therapeutic Goods Administration (TGA), the Australian health regulator that ensures production standards, safety, and the effectiveness of therapeutic products. With the TGA license, the Kemps Creek facility not only meets Australian national standards but also opens opportunities for global expansion and export market penetration.

PYFA President Director, Lee Yan Gwan, affirmed his optimism that the factory will be fully operational by the end of October 2025. “We warmly welcome the operations of the new Probiotec factory. With the TGA license, we are increasingly confident in strengthening our position in Australia and increasing the confidence of current and potential customers to collaborate with PYFA. Currently, the production facility has just started running, and the hope is that, by the end of October at the latest, the Kemps Creek production facility can be fully operational.”

In addition to Australia through Probiotec, PYFA is also strengthening its production capacity through Ethica Industri Farmasi in Indonesia, which is planned to be inaugurated this year. The synergy between world-class facilities in Australia and modernization in Indonesia reaffirms PYFA’s commitment as a trusted pharmaceutical partner providing high-quality healthcare products.